AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23616521 — intervention group
Group type: COMPARATOR
Intervention: Congruent (C)
Number of subjects: 3
Study 23616521 — intervention group
Group type: EXPERIMENTAL
Intervention: Incongruent at preresponse level (PRIC)
Number of subjects: 3
Study 23616521 — intervention group
Group type: EXPERIMENTAL
Intervention: Incongruent at response level (RIC)
Number of subjects: 3
Study 21267072 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyronaridine-artesunate (target dose 7.2:2.4 mg/kg to 13.8:4.6 mg/kg) once daily for three days
Number of subjects: 456
Study 21267072 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine (standard dose) once daily for three days
Number of subjects: 456
Study 21267072 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyronaridine-artesunate
Number of subjects: 456
Study 21267072 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 456
Study 19367302 — intervention group
Group type: EXPERIMENTAL
Intervention: Enforcement of age-restricted tobacco sales in the Central Coast intervention area
Number of subjects: 0
Study 16223754 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray (100 microl per dose)
Number of subjects: 51
Study 16223754 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Number of subjects: 51
Study 16223754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 15349002 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg buprenorphine sublingual
Number of subjects: 6
Study 15349002 — intervention group
Group type: COMPARATOR
Intervention: i.v./sublingual placebo
Number of subjects: 6
Study 15349002 — intervention group
Group type: EXPERIMENTAL
Intervention: escalating i.v. buprenorphine (2, 4, 8, 12, and 16 mg)
Number of subjects: 6
Study 15349002 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. administration
Number of subjects: 6
Study 15349002 — intervention group
Group type: EXPERIMENTAL
Intervention: sublingual administration
Number of subjects: 6
Study 15349002 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg i.v. dose
Number of subjects: 6
Study 15349002 — intervention group
Group type: EXPERIMENTAL
Intervention: buprenorphine
Number of subjects: 6
Study 11739135 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 250 microg twice a day
Number of subjects: 82
Study 11739135 — intervention group
Group type: COMPARATOR
Intervention: Combination of detection and treatment
Number of subjects: 82
Study 9159681 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified BENT incision (oblique incision centered on the steeper meridian)
Number of subjects: 68
Study 9159681 — intervention group
Group type: COMPARATOR
Intervention: Superior incision
Number of subjects: 68
Study 9159681 — intervention group
Group type: COMPARATOR
Intervention: Temporal incision
Number of subjects: 68
Study 9159681 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified BENT incision
Number of subjects: 68
Study 8115730 — intervention group
Group type: EXPERIMENTAL
Intervention: 12% perfluoropropane gas
Number of subjects: 30
Study 8115730 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% perfluoropropane gas
Number of subjects: 30
Study 3617996 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial chemotherapy with MTX and 5-FU (therapy arm A)
Number of subjects: 85
Study 3617996 — intervention group
Group type: COMPARATOR
Intervention: Systemic chemotherapy (therapy arm B)
Number of subjects: 85
Study 3617996 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial chemotherapy
Number of subjects: 85
Study 28548904 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma Passport
Number of subjects: 222
Study 28548904 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma Passport (per-protocol analysis)
Number of subjects: 222
Study 28548904 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 222
Study 26997579 — intervention group
Group type: EXPERIMENTAL
Intervention: APF530 500 mg subcutaneously
Number of subjects: 0
Study 26997579 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 0.15 mg/kg intravenously
Number of subjects: 0
Study 25329446 — intervention group
Group type: EXPERIMENTAL
Intervention: Early presence and high abundance of Moraxella and Corynebacterium/Dolosigranulum
Number of subjects: 60
Study 25329446 — intervention group
Group type: EXPERIMENTAL
Intervention: High abundance of Haemophilus or Streptococcus
Number of subjects: 60
Study 22427029 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotton pledget packing with 4% lignocaine and xylometazoline nasal drops
Number of subjects: 100
Study 22427029 — intervention group
Group type: COMPARATOR
Intervention: Topical spray with 10% lignocaine and xylometazoline drops
Number of subjects: 100
Study 19434508 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate feedback in an intelligent tutoring system (ITS)
Number of subjects: 23
Study 19434508 — intervention group
Group type: COMPARATOR
Intervention: Other metacognitive scaffolds
Number of subjects: 23
Study 18407376 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized volume/weight-based dose reformulation
Number of subjects: 16
Study 18407376 — intervention group
Group type: COMPARATOR
Intervention: Broselow Pediatric Emergency Tape
Number of subjects: 16
Study 15690654 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic J-pouch (n = 36)
Number of subjects: 71
Study 15690654 — intervention group
Group type: COMPARATOR
Intervention: Side-to-end anastomosis (n = 35)
Number of subjects: 71
Study 15690654 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 71
Study 12529662 — intervention group
Group type: EXPERIMENTAL
Intervention: High CD34% in PBSC products (>0.8% CD34+ cells)
Number of subjects: 71
Study 12529662 — intervention group
Group type: COMPARATOR
Intervention: Low CD34% in PBSC products (<=0.8% CD34+ cells)
Number of subjects: 71
Study 12529662 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients evaluable
Number of subjects: 71
Study 12529662 — intervention group
Group type: EXPERIMENTAL
Intervention: High CD34% in PBSC products
Number of subjects: 71
Study 12529662 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoplasia period after induction therapy
Number of subjects: 71
Study 10462235 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular pertussis (aP) vaccine
Number of subjects: 100
Study 10462235 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 100
Study 8690109 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (GNRH‐a) therapy
Number of subjects: 0
Study 8690109 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 1750588 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg dihydrocodeine
Number of subjects: 12
Study 1750588 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg dihydrocodeine
Number of subjects: 12
Study 1750588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 17152744 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteinising hormone releasing hormone (100 microg, i.v.)
Number of subjects: 20
Study 17152744 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrotropin (TSH) releasing hormone (200 microg, i.v.)
Number of subjects: 20
Study 17152744 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular insulin (.1 U/kg, i.v.)
Number of subjects: 20
Study 17152744 — intervention group
Group type: EXPERIMENTAL
Intervention: PRL response in female series
Number of subjects: 20
Study 17152744 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodic analysis of PRL secretion in male patients
Number of subjects: 20
Study 17152744 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 20
Study 31548349 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma 25(OH)D levels (top quintile ≥24.1 ng/mL)
Number of subjects: 1041
Study 29228929 — intervention group
Group type: EXPERIMENTAL
Intervention: VBN-assisted group
Number of subjects: 140
Study 29228929 — intervention group
Group type: COMPARATOR
Intervention: XRF-assisted group
Number of subjects: 140
Study 26179619 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8mg (dose escalated from 0.6 and 1.2mg/day for 1 week each)
Number of subjects: 451
Study 26179619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 451
Study 24385549 — intervention group
Group type: EXPERIMENTAL
Intervention: Weak sense of coherence (SOC)
Number of subjects: 12024
Study 24385549 — intervention group
Group type: COMPARATOR
Intervention: Intermediate sense of coherence (SOC)
Number of subjects: 12024
Study 24385549 — intervention group
Group type: COMPARATOR
Intervention: Strong sense of coherence (SOC)
Number of subjects: 12024
Study 21926065 — intervention group
Group type: EXPERIMENTAL
Intervention: 48-hour training program for community health workers
Number of subjects: 0
Study 21926065 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program implementation
Number of subjects: 0
Study 21926065 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-deployment training
Number of subjects: 0
Study 21926065 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervision by social workers
Number of subjects: 0
Study 21926065 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient encounters
Number of subjects: 0
Study 19540671 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine injections
Number of subjects: 50
Study 19540671 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 50
Study 17468774 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-emptive antibiotic therapy (cefepime administered when neutropenia developed)
Number of subjects: 153
Study 17468774 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-emptive antibiotic therapy (cefepime)
Number of subjects: 153
Study 17468774 — intervention group
Group type: COMPARATOR
Intervention: Empiric antibiotic therapy (cefepime administered at onset of fever and neutropenia)
Number of subjects: 153
Study 15237062 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent priming with alcohol self-assessment just prior to check-up (Group II)
Number of subjects: 409
Study 15237062 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent priming and provider prompting with adolescent self-assessment and brochure (Group III)
Number of subjects: 409
Study 15237062 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Group I)
Number of subjects: 409
Study 15692472 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% cream
Number of subjects: 568
Study 15692472 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 568
Study 10319538 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen 2 mg
Number of subjects: 53
Study 10319538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 8733040 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 20
Study 8733040 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 20
Study 1684991 — intervention group
Group type: EXPERIMENTAL
Intervention: PPA/B (75 mg phenylpropanolamine and 12 mg brompheniramine)
Number of subjects: 13
Study 1684991 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 7139401 — intervention group
Group type: EXPERIMENTAL
Intervention: etomidate 0.3 mg . kg‐1
Number of subjects: 48
Study 7139401 — intervention group
Group type: COMPARATOR
Intervention: alfathesin 75 microliters . kg‐1
Number of subjects: 48
Study 31056710 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch plus nicotine lozenge
Number of subjects: 1067
Study 31056710 — intervention group
Group type: COMPARATOR
Intervention: Nicotine patch alone
Number of subjects: 1067
Study 31056710 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 1067
Study 31056710 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 1067
Study 30280326 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide with carbopol (CPc)
Number of subjects: 70
Study 30280326 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide with natrosol (CPn)
Number of subjects: 70
Study 29362766 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie restriction (CR)
Number of subjects: 75
Study 29362766 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie restriction plus fish oil supplementation (CRF)
Number of subjects: 75
Study 26444330 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy (LLLT - 660 nm, 30 mW, continuous regime, fluency of 10J/cm2) with orthoses
Number of subjects: 30
Study 26444330 — intervention group
Group type: COMPARATOR
Intervention: Orthoses alone
Number of subjects: 30
Study 24517339 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 2313
Study 24517339 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 2313
Study 24517339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2313
Study 24517339 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 2313
Study 21551082 — intervention group
Group type: EXPERIMENTAL
Intervention: ABI <0.9
Number of subjects: 219
Study 21551082 — intervention group
Group type: EXPERIMENTAL
Intervention: ABI >1.3
Number of subjects: 219
Study 21551082 — intervention group
Group type: COMPARATOR
Intervention: Normal ABI
Number of subjects: 219
Study 19946118 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary autologous bone marrow cell (BMC) transfer
Number of subjects: 56
Study 17599484 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting
Number of subjects: 3610
Study 17599484 — intervention group
Group type: COMPARATOR
Intervention: No coronary artery bypass grafting (control)
Number of subjects: 3610
Study 16139175 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (up to 800 mg/day)
Number of subjects: 302
Study 16139175 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (up to 8 mg/day)
Number of subjects: 302
Study 16139175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study 16139175 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 302
Study 16139175 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 302
Study 11851663 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture repair
Number of subjects: 160
Study 11851663 — intervention group
Group type: EXPERIMENTAL
Intervention: Autodermal skin graft
Number of subjects: 160
Study 11851663 — intervention group
Group type: EXPERIMENTAL
Intervention: Onlay polypropylene mesh repair
Number of subjects: 160
Study 11851663 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 160
Study 10223219 — intervention group
Group type: EXPERIMENTAL
Intervention: Sticking plaster treatment
Number of subjects: 57
Study 10223219 — intervention group
Group type: COMPARATOR
Intervention: Epilation (Control)
Number of subjects: 57
Study 7595911 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (27.3 mg daily)
Number of subjects: 22
Study 7595911 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefruside (30.7 mg daily)
Number of subjects: 22
Study 30837600 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss and regain (diet group)
Number of subjects: 42
Study 30837600 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study 30514841 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethnically diverse papers
Number of subjects: 6000000
Study 30514841 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethnically diverse scientists
Number of subjects: 6000000
Study 26767505 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg daily for 24 weeks combined with NB-UVB
Number of subjects: 120
Study 26767505 — intervention group
Group type: COMPARATOR
Intervention: NB-UVB monotherapy
Number of subjects: 120
Study 25185628 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor physical therapy (PFPT) biweekly until 12 weeks postoperatively
Number of subjects: 49
Study 25185628 — intervention group
Group type: COMPARATOR
Intervention: Standard care (physician assessment alone)
Number of subjects: 49
Study 23059199 — intervention group
Group type: EXPERIMENTAL
Intervention: Early antiretroviral therapy (started at study entry)
Number of subjects: 300
Study 23059199 — intervention group
Group type: COMPARATOR
Intervention: Deferred antiretroviral therapy (started when CD4 percentage declined to less than 15%)
Number of subjects: 300
Study 19570887 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.86% peritoneal equilibration test (PET)
Number of subjects: 90
Study 19570887 — intervention group
Group type: COMPARATOR
Intervention: 2.27% peritoneal equilibration test (PET)
Number of subjects: 90
Study 17215629 — intervention group
Group type: EXPERIMENTAL
Intervention: Qi gong training (16-week medically assisted program)
Number of subjects: 43
Study 17215629 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 43
Study 15570025 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein isolate (26 +/- 5 g soy protein containing 44 +/- 8 mg isoflavones/d)
Number of subjects: 37
Study 15570025 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein isolate + probiotic capsules (10^9 colony-forming units Lactobacillus acidophilus DDS-1 and Bifidobacterium longum)
Number of subjects: 37
Study 15570025 — intervention group
Group type: COMPARATOR
Intervention: Milk protein isolate (26 +/- 5 g milk protein/d)
Number of subjects: 37
Study 15570025 — intervention group
Group type: COMPARATOR
Intervention: Milk protein isolate + probiotic
Number of subjects: 37
Study 15570025 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy treatments in hypercholesterolemic women (TC > 5.17 mmol/L)
Number of subjects: 37
Study 11482548 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (3x5 g x day(-1))
Number of subjects: 42
Study 11482548 — intervention group
Group type: COMPARATOR
Intervention: Iso-nitrogenated placebo (3x10 g x day(-1))
Number of subjects: 42
Study 9773719 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 114
Study 9773719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 7919354 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg/m2 busulfan
Number of subjects: 22
Study 7919354 — intervention group
Group type: COMPARATOR
Intervention: 4 mg/kg busulfan
Number of subjects: 22
Study 2448408 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated oral estrogens (0.625 mg daily)
Number of subjects: 23
Study 2448408 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated oral estrogens (1.25 mg daily)
Number of subjects: 23
Study 2448408 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermally administered estradiol (25 micrograms/24 hr)
Number of subjects: 23
Study 2448408 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermally administered estradiol (50 micrograms/24 hr)
Number of subjects: 23
Study 2448408 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermally administered estradiol (100 micrograms/24 hr)
Number of subjects: 23
Study 2448408 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermally administered estradiol (200 micrograms/24 hr)
Number of subjects: 23
Study 31832733 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinoplasty surgery
Number of subjects: 100
Study 30478263 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled seizures
Number of subjects: 270
Study 30478263 — intervention group
Group type: EXPERIMENTAL
Intervention: Seizure attacks 1-5 times
Number of subjects: 270
Study 30478263 — intervention group
Group type: EXPERIMENTAL
Intervention: Seizure attacks 6-10 times
Number of subjects: 270
Study 30478263 — intervention group
Group type: EXPERIMENTAL
Intervention: Seizure attacks greater than 10 times
Number of subjects: 270
Study 30478263 — intervention group
Group type: COMPARATOR
Intervention: Alcohol consumption
Number of subjects: 270
Study 30478263 — intervention group
Group type: COMPARATOR
Intervention: Negative medication belief
Number of subjects: 270
Study 30478263 — intervention group
Group type: COMPARATOR
Intervention: Low medication adherence
Number of subjects: 270
Study 30478263 — intervention group
Group type: COMPARATOR
Intervention: Presence of comorbidities
Number of subjects: 270
Study 28677237 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Vitamin B12-barrier cream (MB12)
Number of subjects: 22
Study 28677237 — intervention group
Group type: COMPARATOR
Intervention: Standard glycerol-petrolatum-based emollient cream (GPC)
Number of subjects: 22
Study 26511956 — intervention group
Group type: EXPERIMENTAL
Intervention: Motavizumab (15 mg/kg, five monthly intramuscular doses)
Number of subjects: 2127
Study 26511956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2127
Study 26511956 — intervention group
Group type: EXPERIMENTAL
Intervention: Motavizumab
Number of subjects: 2127
Study 24386076 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial colposcopy with biopsies and/or subsequent treatment based on colposcopic and histological findings (n = 1696)
Number of subjects: 3399
Study 24386076 — intervention group
Group type: COMPARATOR
Intervention: Cytological surveillance (six-monthly tests; n = 1703)
Number of subjects: 3399
Study 24386076 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial colposcopy
Number of subjects: 3399
Study 24386076 — intervention group
Group type: COMPARATOR
Intervention: Cytological surveillance
Number of subjects: 3399
Study 21228029 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine tablets (3.5 mg/kg cumulative dose over 96 weeks)
Number of subjects: 1326
Study 21228029 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine tablets (5.25 mg/kg cumulative dose over 96 weeks)
Number of subjects: 1326
Study 21228029 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine tablets
Number of subjects: 1326
Study 21228029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1326
Study 18224269 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium + 20 microg (800 IU) vitamin D3
Number of subjects: 208
Study 18224269 — intervention group
Group type: COMPARATOR
Intervention: Calcium alone
Number of subjects: 208
Study 18224269 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (calcium alone and calcium + vitamin D3)
Number of subjects: 208